RecruitingPhase 2NCT05851391

buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest

buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest (RESTORE)


Sponsor

University of California, San Francisco

Enrollment

30 participants

Start Date

Aug 7, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

RESTORE is a randomized clinical trial investigating the safety and feasibility of using EEG treatment targets (burst suppression vs. seizure suppression) for post-cardiac arrest refractory status epilepticus treatment.


Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Age ≥18 years old
  • Non-traumatic, out-of-hospital cardiac arrest
  • Comatose on admission - defined as not following commands
  • Return of spontaneous circulation (ROSC) within less than 45 minutes
  • Admission to the intensive care unit
  • Diagnosis of post-cardiac arrest refractory status epilepticus confirmed with continuous
  • EEG monitoring within 7 days from ROSC

Exclusion Criteria3

  • Acute cerebral hemorrhage or infarction
  • Pregnancy
  • Prisoners

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBurst Suppression EEG Target Intravenous Anesthesia

The objective of the burst suppression EEG target is to stop seizures by titrating the anesthetic infusion to suppress most of the EEG background (\>50% suppressed/attenuated). After this 24-hour period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.

DRUGSeizure Suppression EEG Target Intravenous Anesthesia

is to stop seizures by titrating the anesthetic infusion without suppressing most of the EEG background. This target would be continued for 24 hours. After this 24-hours period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.


Locations(1)

Zuckerberg San Francisco General Hospital

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05851391


Related Trials